Abstract
The hepatocyte growth factor (HGF)/Met receptor tyrosine kinase signaling pathway is an essential regulator of cell proliferation, motility, and morphogenesis during embryogenesis, early development, and adult homeostasis. Signaling is directly regulated at several levels, including HGF proteolytic activation, receptor and proteoglycan binding, receptor phosphorylation, and ligand-receptor complex internalization and degradation. In many types of cancer, events that undermine these features can lead to aberrant pathway activation and contribute to oncogenesis, tumor angiogenesis and invasiveness, and tumor metastasis. Advanced drug design strategies and lessons learned from other growth factor/tyrosine kinase-targeted drug programs fueled the rapid development of potent and highly selective HGF/Met-targeted drug candidates. Meaningful clinical responses from early-phase clinical trials have been reported in lung, gastric, prostate, and papillary renal cancer patients treated with HGF and Met inhibitors. Yet, most of these agents have not advanced beyond phase II testing, a few stopped in phase III trials, and many HGF/Met-targeted drug development programs have been halted. No selective Met pathway inhibitors have been FDA approved for a disease where Met is thought to be a primary contributor. Underlying this unanticipated failure are a multitude of factors, but inadequate development of clinical tests for HGF/Met pathway activity and criticality appears to have been a critical weakness. This realization, our growing awareness of the molecular diversity of oncogenic defects in solid tumors, the need to modernize clinical trial design for testing highly targeted drugs as single agents, and the need to better translate combination therapies from model systems to human patients, should prevent us from discarding drugs that may have unrealized clinical utility, and help us identify indications and patients where they are most efficacious.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- CRC:
-
Colorectal carcinoma
- EGFR:
-
Epidermal growth factor receptor
- GC:
-
Gastric carcinoma
- HGF:
-
Hepatocyte growth factor
- IHC:
-
Immunohistochemistry
- IPT:
-
Ig-like, plexins, transcription factors
- JM:
-
Juxtamembrane
- MM:
-
Multiple myeloma
- MST1R:
-
Macrophage stimulating 1 receptor
- OS:
-
Overall survival
- PD:
-
Pharmacodynamic
- PFS:
-
Progression-free survival
- PRC:
-
Papillary renal cell carcinoma
- PSI:
-
Plexins, semaphorins, and integrins
- RCC:
-
Renal cell carcinoma
- SCLC:
-
Small lung cell cancer
- SH2:
-
Src homology-2
- TK:
-
Tyrosine kinase
- TKI:
-
TK inhibitor
- TPR:
-
Translocated promoter region
References
Rubin JS, Bottaro DP. UCSD molecule pages: HGF. 2011. URL: http://www.signaling-gateway.org/molecule/query?afcsid=A004032.
Peschard P, Park M. From Tpr-Met to Met, tumorigenesis and tubes. Oncogene. 2007;26:1276–85.
Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12:89–103.
Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347–61.
Peruzzi B, Athauda G, Bottaro DP. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc Natl Acad Sci U S A. 2006;103:14531–6.
Lee YH, Morrison BL, Bottaro DP. Synergistic signaling of tumor cell invasiveness by hepatocyte growth factor and hypoxia. J Biol Chem. 2014;289:20448–61.
Corso S, Migliore C, Ghiso E, et al. Silencing the MET oncogene leads to regression of experimental tumors and metastases. Oncogene. 2008;27:684–93.
Dharmawardana PG, Giubellino A, Bottaro DP. Hereditary papillary renal carcinoma type I. Curr Mol Med. 2004;4:855–68.
Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16:553–72.
Salgia R. MET in lung cancer: biomarker selection based on scientific rationale. Mol Cancer Ther. 2017 Apr;16(4):555–65.
Cappuzzo F, Varella-Garcia M, Finocchiaro G, et al. Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients. Br J Cancer. 2008;99:83–9.
Kim JY, Welsh EA, Fang B, Bai Y, Kinose F, Eschrich SA, et al. Phosphoproteomics reveals MAPK inhibitors enhance MET- and EGFR-driven AKT signaling in KRAS-mutant lung cancer. Mol Cancer Res. 2016;14(10):1019–29.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–8.
International Cancer Genome Consortium PedBrain Tumor, Project. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med. 2016;22:1314–20.
Bao ZS, Chen HM, Yang MY, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 2014;24:1765–73.
Isozaki H, Ichihara E, Takigawa N, et al. Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases. Cancer Res. 2016;76:1506–16.
Horwitz E, Stein I, Andreozzi M, et al. Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. Cancer Discov. 2014;4:730–43.
Kentsis A, Reed C, Rice KL, et al. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012;18:1118–22.
Yano S, Takeuchi S, Nakagawa T, et al. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci. 2012;103:1189–94.
Straussman R, Morikawa T, Shee K, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500–4.
Leung E, Xue A, Wang Y, et al. Blood vessel endothelium-directed tumor cell streaming in breast tumors requires the HGF/C-Met signaling pathway. Oncogene. 2017;36:2680–92.
Kawaguchi M, Kataoka H. Mechanisms of hepatocyte growth factor activation in cancer tissues. Cancer. 2014;6:1890–904.
Peinado H, Alečković M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012;18:883–91.
Adachi E, Sakai K, Nishiuchi T, et al. Cell-autonomous changes in Met receptor expression regulate the growth and metastatic characteristics in malignant melanoma. Oncotarget. 2016;43:70779–93.
Jun HT, Sun J, Rex K, et al. AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts. Clin Cancer Res. 2007;13:6735–42.
Jones SF, Cohen RB, Bendell JC, et al. Safety, tolerability, and pharmacokinetics of TAK-701, a humanized anti-hepatocyte growth factor (HGF) monoclonal antibody, in patients with advanced nonhematologic malignancies: first-in-human phase I dose-escalation study. J Clin Oncol. 2010;28:15s. (suppl abstr 3081), American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL
Tan K, Park K, Lim M, et al. Phase Ib study of ficlatuzumab (formerly AV-299), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb) in combination with gefitinib (G) in Asian patients (pts) with NSCLC. J Clin Oncol. 2011;29 (Suppl Abstract 7571), American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, 2011;7571–7571.
Rolfo C, Van Der Steen N, et al. Onartuzumab in lung cancer: the fall of Icarus? Expert Rev Anticancer There. 2015;15:487–9.
U.S. Food and Drug Administration. Cabozantinib. URL: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm.
Gordon MS, Vogelzang NJ, Schoffski P, et al. Activity of cabozantinib (XL184) in soft tissue and bone: results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors. J Clin Oncol. 2011;29:(Suppl; Abstract 3010) 3010–3010.
Wen PY, Prados M, Schiff D, et al. Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB). J Clin Oncol. 2010;28 (Suppl Abstract 2006). American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL.
Vaishampayan U. Cabozantinib as a novel therapy for renal cell carcinoma. Curr Oncol Rep. 2013;15:76–82.
Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.
Yau TC, Lencioni R, Sukeepaisarnjaroen W, et al. A phase I/II multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2017;23:2405–13.
Molife LR, Dean EJ, Blanco-Codesido M, et al. A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors. Clin Cancer Res. 2014;20:6284–94.
Jia Y, Juarez J, Li J, Manuia M, et al. EGF816 exerts anticancer effects in non-small cell lung cancer by irreversibly and selectively targeting primary and acquired activating mutations in the EGF receptor. Cancer Res. 2016;76:1591–602.
Srivastava AK, Hollingshead MG, Weiner J, et al. Pharmacodynamic response of the MET/HGF receptor to small-molecule tyrosine kinase inhibitors examined with validated, fit-for-clinic immunoassays. Clin Cancer Res. 2016;22:3683–94.
Li L, Puliyappadamba VT, Chakraborty S, et al. EGFR wild type antagonizes EGFRvIII-mediated activation of Met in glioblastoma. Oncogene. 2015;34:129–34.
Cecchi F, Wright C, Bottaro DP. Experimental therapeutics targeting the hepatocyte growth factor/Met signaling pathway. 2017;URL: https://ccrod.cancer.gov/confluence/display/CCRHGF/Home.
Bellon SF, Kaplan-Lefko P, Yang Y, Zhang Y, et al. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. J Biol Chem. 2008;283(5):2675–83.
Norman MH, Liu L, Lee M, et al. Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives. J Med Chem. 2012;55(5):1858–67.
Johnson J, Ascierto ML, Mittal S, et al. Genomic profiling of a hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. J Transl Med. 2015;13:306.
Bahcall M, Sim T, Paweletz CP, et al. Acquired METD1228V mutation and resistance to MET inhibition in lung cancer. Cancer Discov. 2016;6:1334–41.
Du Y, Yamaguchi H, Wei Y, et al. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med. 2016;22:194–201.
Kammerer-Jacquet SF, Medane S, Bensalah K, et al. Correlation of c-MET expression with PD-L1 expression in metastatic clear cell renal cell carcinoma treated by sunitinib first-line therapy. Target Oncol. 2017;12:487–494.
Chen GZ, Dai WS, Zhu HC, et al. Foretinib enhances the radiosensitivity in esophageal squamous cell carcinoma by inhibiting phosphorylation of c-Met. J Cancer. 2017;8:983–92.
Cascone T, Xu L, Lin HY, et al. The HGF/c-MET pathway is a driver and biomarker of VEGFR-inhibitor resistance and vascular remodeling in non-small cell lung cancer. Clin Cancer Res. 2017;23:5489-5501.
Krepler C, Xiao M, Sproesser K, et al. Personalized preclinical trials in BRAF inhibitor-resistant patient-derived xenograft models identify second-line combination therapies. Clin Cancer Res. 2016;22:1592–602.
Acknowledgments
This work was supported by the Intramural Research Program of the NIH (ZIA BC011124 awarded to DPB), National Cancer Institute, Center for Cancer Research.
Disclosure Statement
The authors disclose no conflicts of interest, financial or otherwise.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
De Silva, D.M., Roy, A., Kato, T., Bottaro, D.P. (2019). Met Signaling in Carcinogenesis. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)